# Evaluation of Prostate-Specific Antigen (PSA) Levels in Patients With Advanced Prostate Cancer Treated With Bicalutamide

> **NCT00871585** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 340 (actual)

## Conditions studied

- Advanced Prostate Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT00871585
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 340 (ACTUAL)
- **Last updated:** 2010-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00871585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00871585, "Evaluation of Prostate-Specific Antigen (PSA) Levels in Patients With Advanced Prostate Cancer Treated With Bicalutamide". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00871585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*